A股龍佰集團擬本月赴港遞交上市申請 集資至少62億港元
格隆匯9月1日丨據香港經濟日報,龍佰集團(002601.SZ)擬來港上市,籌集8億到10億美元(約62.22億至77.77億港元),最快於今年9月遞交上市申請,中金、國泰君安及廣發證券正與公司合作上市事宜。龍佰集團是一家大型化工集團,主要從事鈦白粉、海綿鈦、鈷製品和硫酸等產品的生產與銷售,也是亞洲最大的鈦白粉企業。龍佰集團亦通過新建項目、合作、收購等方式進入新能源電池領域。龍佰集團上半年純利按年升88.3%至24.35億元(人民幣,下同),營業收入升55.3%至98.4億元。龍佰集團最早於今年4月透露有意來港上市,於8月中旬已向中證監會提交《境外首次公開發行股份審批》材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.